BioCentury | Oct 17, 2016
Clinical News

ECCS-50: Completed Phase II enrollment

...Bimini Technologies , San Diego, Calif. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego, Calif. Product: ECCS-50, ECCO-50...
BioCentury | Feb 15, 2016
Clinical News

ECCS-50: Phase IIb data

...patients with chronic knee pain due to OA showed that a single intra-articular injection of ECCO-50...
...or 40 million cells of ECCO-50. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego, Calif. Product: ECCS-50, ECCO-50...
BioCentury | Sep 7, 2015
Clinical News

ECCI-50: Phase III started

...or benign prostatic hypertrophy. Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: ECCI-50 , ECCO-50...
BioCentury | Jul 13, 2015
Clinical News

Adipose-derived regenerative cells: Completed Phase IIb enrollment

...double-blind, placebo-controlled, U.S. Phase IIb ACT-OA trial evaluating 2 dose levels of intra-articular injections of ECCO-50...
...NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Adipose-derived regenerative cells (ADRCs) ( Cytori Cell Therapy , ECCO-50...
BioCentury | Mar 2, 2015
Clinical News

Adipose-derived regenerative cells: Phase II started

...placebo-controlled, U.S. Phase II ACT-OA trial to evaluate 2 dose levels of intra-articular injections of ECCO-50...
...NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Adipose-derived regenerative cells (ADRCs) ( Cytori Cell Therapy , ECCO-50...
Items per page:
1 - 5 of 5